Rigosertib for RDEB-SCC

计划入组 2 人 · 首次发布于 2018 年 12 月 24 日

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

计划入组 16 人 · 首次发布于 2024 年 12 月 13 日

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

计划入组 22 人 · 首次发布于 2023 年 2 月 1 日

SCC-31

enzyme/protein replacement therapy (RDEB)

Head&neck SCC(Asylia Diagnostics)

Associated Capital

United States

Associated Medical Supplies Ltd

Canada

Associated Clinicians of East Texas, PLLC

United States

Rigosertib Achieves 80% Response Rate in First Clinical Trial for Rare RDEB-Associated Skin Cancer

Losartan Use Safely Eases RDEB Symptoms in Children, Trial Data Shows

INmune Bio Plans FDA Submission for CORDStrom in Rare Skin Disease RDEB